Observational studyJournal of hypertension2025
The effects of propionate on blood pressure and arterial function.
Observational study in Journal of hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.Gut pathogens · 2026Review
- Protective effects of fermentable dietary fiber and propionate in Dahl salt-sensitive hypertension and renal damage.American journal of physiology. Renal physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The short-chain fatty acid propionate has been shown to attenuate atherosclerosis, for example by modulating intestinal cholesterol metabolism. Beyond cholesterol metabolism, data from rodent models suggest a potential additional effect on blood pressure reduction. We conducted a prospective uncontrolled, exploratory, and observational study on 58 individuals receiving propionate supplementation (500 mg twice daily) without preexisting atherosclerotic cardiovascular disease, assessing peripheral and central blood pressure, arterial stiffness, and endothelial function. All parameters were measured at baseline and follow-up after 3 months. Propionate supplementation was associated with a significant reduction in peripheral systolic (-2.4 mmHg, P = 0.0181, Cohen's d = 0.17) and diastolic (-2.5 mmHg, P = 0.0155, Cohen's d = 0.27) blood pressure, as well as central DBP (-2.4mmHg, P = 0.0198, Cohen's d = 0.26). Regulatory T-cell frequency increased significantly ( P = 0.0036). No changes were observed in pulse wave velocity, flow-mediated dilatation, and cytokine concentrations. Propionate supplementation is associated with a mild reduction in blood pressure in a rather normotensive population of individuals without preexisting atherosclerotic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.